2030 Drug Development Pharmaceutical Companies 
European Pharmaceutical Review
SEPTEMBER 12, 2023
Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development , within the next 24-months. Attending CPHI Barcelona 2023?
European Pharmaceutical Review
AUGUST 17, 2022
According to a recent report , the global formulation development outsourcing market size should grow to $61.4 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 Pharmaceutical companies globally are significantly investing in R&D. percent from its 2022 value of $35.1
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
APRIL 3, 2024
Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. percent between 2022-2030. The report noted that there has been “considerable” merger and acquisition activity in recent years within the pharmaceutical contract manufacturing market.
Express Pharma
JULY 21, 2024
Recognising the pharmaceutical industry’s substantial contribution to India’s exports, we eagerly anticipate schemes that provide fiscal incentives to encourage such exports. Indian Pharmaceutical sector trying to reach the USD 130 Billion target by 2030. This may fuel innovation, particularly for diseases prevalent in India.
European Pharmaceutical Review
SEPTEMBER 21, 2023
billion by 2030. In this Q&A, Karen Pinachyan, Head of Medical Affairs Europe at CSL Behring summarises key considerations for gene therapy drug development and the ideal approach for alleviating economic strain when advancing these modern treatments. How has the gene therapy landscape evolved over the last several years?
pharmaphorum
JUNE 8, 2021
“But we are glad to see the situation for innovative drugs in Asian markets improving, especially in mainland China and South Korea, where policies, societies and regulations are actively promoting innovation. “At At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home.
pharmaphorum
MARCH 10, 2022
“As pipelines shift towards biotechnology, all companies will have to decide between investing in expertise in-house and relying on the pre-existing technological platforms offered by experienced companies.”. As such, companies are rethinking the existing landscape of drug development. The rise of biologics.
Expert insights. Personalized for you.
105 
Let's personalize your content